NZYM B Novozymes A/S Class B

Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%

Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%

COPENHAGEN, Denmark – August 21, 2025. Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%.

Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth. Our profitability also remains solid, despite strong headwinds from currencies. With a strong foundation in place, we are well positioned to accelerate into our next strategy period until 2030, where we will continue to significantly invest in what makes Novonesis unique, further strengthening our position while expanding the biosolutions market."

Highlights of our H1 results: 

· Strong organic sales growth of 9% (Q2: 8%), including ~1pp from price (Q2: ~1pp). Food & Health at 10% organic sales growth (Q2: 9%); Planetary Health at 9% organic sales growth (Q2: 7%).

· Emerging markets organic sales growth at 12% (Q2: 10%) and developed markets at 8% (Q2: 6%).

· Cost synergies now at 100% run rate compared to 80% previously.

· Adjusted EBITDA margin at 37.4% (Q2: 36.4%), up by 210 bps (Q2: 100 bps).

· Adjusted net profit increased by 23% (Q2: 19%).

· NIBD/EBITDA at 2.1x, including the closed acquisition of dsm-firmenich’s part of the Feed Enzyme Alliance on June 2, 2025.

· Completion of the EUR 100 million share buyback program on June 27.

· 2025 outlook: Organic sales growth range narrowed to 6-8% (previously 5-8%), and 7-9% excluding the exit from certain countries (previously 6-9%). Adjusted EBITDA margin is maintained at 37-38%, despite strong currency headwinds.

· Interim dividend of 2.25 DKK (EUR 0.30) approved for the first half of 2025.

· Novonesis announced its long-term financial targets towards 2030. Please refer to Company Announcement on the 2030 ‘GROW’ strategy on August 20, 2025.

The 2030 strategy will be presented and commented on in combination with the extended H1 2025 conference call on August 21 at 09.00 CET. Slides will be shared ahead of the conference call. Here is the link to the conference call:  

Contact information 

Investor Relations 

Tobias Bjorklund, ,   

Anders Enevoldsen, ,   

Katrine Spedtsberg Poulsen,   

Media Relations 

Jens Gamborg, ,   

Attachment



EN
21/08/2025

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

February 27, 2026 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full annuncement in PDF. Attachment

February 26, 2026 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Invitation to the 2026 Annual General Meeting

Invitation to the 2026 Annual General Meeting The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark. For further information, please refer to the enclosed invitation to convene the Annual General Meeting, including the agenda and complete proposals. BOARD OF DIRECTORSThe Board of Directors proposes the re-election of Cornelis (Cees) de Jong as Chair of the Board and Heine Da...

February 26, 2026 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The Executive Leadership Team members eligible for the Novozymes A/S 2023-2025 incentive program has on February 25, 2026, received the allocated shares. An overview of the number and value of shares allotted is provided...

February 26, 2026 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Novonesis delivered strong organic sales growth of 7% in 2025

Novonesis delivered strong organic sales growth of 7% in 2025 COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall.  Ester Baiget, President & CEO:  “In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a...

February 25, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch